{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:16:36Z","timestamp":1790403396251,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The onset of new conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) is still a relevant adverse event. The main objective of this registry was to identify modifiable procedural risk factors for an improved outcome (lower rate of PPI) after TAVI in patients at high risk of PPI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients from four European centres receiving a balloon-expandable TAVI (Edwards SAPIEN 3\/3 Ultra) and considered at high risk of PPI (pre-existing conduction disturbance, heavily calcified left ventricular outflow tract or short membranous septum) were prospectively enrolled into registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 300 patients were included: 42 (14.0%) required PPI after TAVI and 258 (86.0%) did not. Patients with PPI had a longer intensive care unit plus intermediate care stay (65.7 vs 16.3\u2009hours, p&lt;0.001), general ward care stay (6.9 vs 5.3\u2009days, p=0.004) and later discharge (8.6 vs 5.0\u2009days, p&lt;0.001). Of the baseline variables, only pre-existing right bundle branch block at baseline (OR 6.8, 95% CI 2.5 to 18.1) was significantly associated with PPI in the multivariable analysis. Among procedure-related variables, oversizing had the highest impact on the rate of PPI: higher than manufacturer-recommended sizing, mean area oversizing as well as the use of the 29\u2009mm valve (OR 3.4, 95% CI 1.4 to 8.5, p=0.008) all were significantly associated with PPI. Rates were higher with the SAPIEN 3 (16.1%) vs SAPIEN 3 Ultra (8.5%), although not statistically significant but potentially associated with valve sizing. Implantation depth and postdelivery balloon dilatation also tended to affect PPI rates but without a statistical significance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Valve oversizing is a strong procedure-related risk factor for PPI following TAVI. The clinical impact of the valve type (SAPIEN 3), implantation depth, and postdelivery balloon dilatation did not reach significance and may reflect already refined procedures in the participating centres, giving attention to these avoidable risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03497611\">NCT03497611<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2022-002191","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T12:06:02Z","timestamp":1675771562000},"page":"e002191","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Modifiable risk factors for permanent pacemaker after transcatheter aortic valve implantation: CONDUCT registry"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03497611","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tanja","family":"Rudolph","sequence":"first","affiliation":[{"name":"Department of Cardiology, Cologne University, Cologne, Germany"},{"name":"Clinic for General and Interventional Cardiology\/Angiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-7615","authenticated-orcid":false,"given":"Michal","family":"Droppa","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Hospital T\u00fcbingen, Tubingen, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Baan","sequence":"additional","affiliation":[{"name":"Heart Center, University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels-Erik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Baranowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Hachaturyan","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kurucova","sequence":"additional","affiliation":[{"name":"Edwards Lifesciences, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hack","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cologne University, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[{"name":"Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Hospital T\u00fcbingen, Tubingen, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"2025081709531556000_10.1.e002191.1","first-page":"644","article-title":"Transcatheter versus surgical aortic valve replacement in moderate and high-risk patients: a meta-analysis","volume":"51","author":"Carnero-Alc\u00e1zar","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025081709531556000_10.1.e002191.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008232"},{"key":"2025081709531556000_10.1.e002191.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1514616"},{"key":"2025081709531556000_10.1.e002191.4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/HCO.0000000000000813","article-title":"Two-Year outcomes from the partner 3 trial: where do we stand?","volume":"36","author":"Muller Moran","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2025081709531556000_10.1.e002191.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103510"},{"key":"2025081709531556000_10.1.e002191.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"2025081709531556000_10.1.e002191.7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12928-017-0477-6","article-title":"New generation devices for Transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome","volume":"33","author":"Seeger","year":"2018","journal-title":"Cardiovasc Interv Ther"},{"key":"2025081709531556000_10.1.e002191.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.07.022"},{"key":"2025081709531556000_10.1.e002191.9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4244\/EIJY14M11_06","article-title":"Unravelling the (arte)fact of increased pacemaker rate with the edwards SAPIEN 3 valve","volume":"11","author":"Tarantini","year":"2015","journal-title":"EuroIntervention"},{"key":"2025081709531556000_10.1.e002191.10","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jev343"},{"key":"2025081709531556000_10.1.e002191.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.09.036"},{"key":"2025081709531556000_10.1.e002191.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.12.023"},{"key":"2025081709531556000_10.1.e002191.13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/joic.12302","article-title":"Optimized implantation height of the Edwards SAPIEN 3 valve to minimize pacemaker implantation after TAVI","volume":"29","author":"Schwerg","year":"2016","journal-title":"J Interv Cardiol"},{"key":"2025081709531556000_10.1.e002191.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.08.034"},{"key":"2025081709531556000_10.1.e002191.15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00392-017-1093-2","article-title":"Predictors for permanent pacemaker implantation in patients undergoing Transfemoral aortic valve implantation with the Edwards sapien 3 valve","volume":"106","author":"Gonska","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2025081709531556000_10.1.e002191.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2016.11.020"},{"key":"2025081709531556000_10.1.e002191.17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.015896","article-title":"Pacemaker implantation after balloon- or self-expandable transcatheter aortic valve replacement in patients with aortic stenosis","volume":"9","author":"Bisson","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025081709531556000_10.1.e002191.18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00380-020-01653-6","article-title":"Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis","volume":"35","author":"Droppa","year":"2020","journal-title":"Heart Vessels"},{"key":"2025081709531556000_10.1.e002191.19","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/eurheartj\/ehx785","article-title":"Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review","volume":"39","author":"van Rosendael","year":"2018","journal-title":"Eur Heart J"},{"key":"2025081709531556000_10.1.e002191.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.033"},{"key":"2025081709531556000_10.1.e002191.21","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/clc.23475","article-title":"Effects of COPD on in-hospital outcomes of transcatheter aortic valve implantation: results from the National inpatient sample database","volume":"43","author":"Xiao","year":"2020","journal-title":"Clin Cardiol"},{"key":"2025081709531556000_10.1.e002191.22","first-page":"570","article-title":"The relationship between chronic obstructive pulmonary disease and transcatheter aortic valve implantation -- a systematic review and meta-analysis","volume":"87 Suppl 1","author":"Liao","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2025081709531556000_10.1.e002191.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.000482"},{"key":"2025081709531556000_10.1.e002191.24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.25270\/jic\/19.00348","article-title":"Impact of left ventricular outflow tract calcification on pacemaker implantation after transcatheter aortic valve implantation with second-generation devices","volume":"32","author":"Ancona","year":"2020","journal-title":"J Invasive Cardiol"},{"key":"2025081709531556000_10.1.e002191.25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.acvd.2017.03.004","article-title":"Incidence, indications and predicting factors of permanent pacemaker implantation after transcatheter aortic valve implantation: a retrospective study","volume":"110","author":"Becker","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"2025081709531556000_10.1.e002191.26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020906","article-title":"Predictors of permanent pacemaker implantation in patients undergoing transcatheter aortic valve replacement - a systematic review and meta-analysis","volume":"10","author":"Ullah","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025081709531556000_10.1.e002191.27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.recesp.2018.05.042","article-title":"Multicenter evaluation of prosthesis oversizing of the SAPIEN 3 transcatheter heart valve. impact on device failure and new pacemaker implantations","volume":"72","author":"Pellegrini","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025081709531556000_10.1.e002191.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.03.030"},{"key":"2025081709531556000_10.1.e002191.29","doi-asserted-by":"crossref","first-page":"Q83","DOI":"10.4244\/EIJV8SQA15","article-title":"Edwards sapien 3 valve","volume":"8 Suppl Q","author":"Binder","year":"2012","journal-title":"EuroIntervention"},{"key":"2025081709531556000_10.1.e002191.30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/jce.14986","article-title":"Predictors of permanent pacemaker insertion after TAVR: a systematic review and updated meta-analysis","volume":"32","author":"Mahajan","year":"2021","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2022-002191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:53:24Z","timestamp":1755449604000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2022-002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/openhrt-2022-002191"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2022-002191","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}